



**Date: 4 December 2019**

**Sydney, Australia**

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

## **Nyrada Inc. – Initial Public Offering Opens**

---

- **A U.S. subsidiary of Noxopharm Ltd**
  - **A biotechnology company focusing on small molecule, non-oncology assets**
  - **Raising A\$7,000,000 (Minimum Subscription) to A\$8,500,000 (Maximum Subscription)**
  - **Issuance of CHESS Depository Interests**
- 

**Sydney, 4 December 2019:** Noxopharm (ASX:NOX) announces the opening of the offer period under the Prospectus relating to the Initial Public Offering (IPO) of Nyrada Inc. ('Nyrada') (ARBN 625 401 818). Nyrada also is seeking a listing on the Australian Securities Exchange (ASX) in conjunction with the IPO.

Nyrada is a U.S.-incorporated company established by Noxopharm in 2017 for the purpose of developing drugs across the three areas of cardiovascular, neurological and inflammatory diseases and disorders.

Nyrada is seeking to raise up to AU\$8,500,000 to conduct its business of drug development.

Nyrada intends to seek a listing on the ASX as a foreign company registered in Australia through the issue of securities known as CHESS Depository Interests (CDIs).

The offer of CDIs by Nyrada is made in, or accompanied by, the Prospectus. The electronic version of the Prospectus and the Application Form for the CDIs are available for download on both the Noxopharm and Nyrada websites: [www.noxopharm.com](http://www.noxopharm.com) and [www.nyrada.com](http://www.nyrada.com).

Potential investors should consider the Prospectus in deciding whether to acquire CDIs in Nyrada.

Anyone wishing to acquire CDIs in Nyrada will need to follow the instructions in the Prospectus and complete the Application Form that is in or will accompany the Prospectus.

**About Noxopharm**

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder of Nyrada Inc.

[www.noxopharm.com](http://www.noxopharm.com)

**Investor & Corporate Enquiries:**

Prue Kelly

M: 0459 022 445

E: [info@noxopharm.com](mailto:info@noxopharm.com)

**Company Secretary:**

David Franks

T: +61 2 9299 9690

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

**Media queries:**

Catherine Strong

Citadel-MAGNUS

T: 02 8234 0111

E: [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.